Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Palisade Bio Inc
PALI
Healthcare
Biotechnology
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD...
can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PALI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
Next
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 08, 2024 11:00pm
Palisade Bio Announces Formation of Clinical Advisory Board
News; $PALI Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion LeadersBruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn
...more
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 29, 2024 12:30pm
Dow Edges Lower; Cardlytics Shares Jump | Benzinga
Just In: $PALI Dow Edges Lower; Cardlytics Shares Jump | BenzingaU.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday.The Dow traded down 0.04%
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(228)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 29, 2024 10:00am
Palisade Bio Announces Positive Preclinical Data of Lead Pro
News; $PALI Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress@ Preclinical data demonstrated PALI-2108 to be safe and well
...more
(7)
•••
Chart1
X
View Profile
View Bullboard History
Post by
Chart1
on Sep 29, 2023 1:46am
Bought in to this pos
The company is a disaster. Purely a trade for me here. A postion average at 0.54 . These dummies will pump this again to raise more money. I'll be exiting when they do. All these companies follow
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 11, 2023 4:01pm
New Press Release - Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 11, 2023 8:35am
New Press Release - Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Announces Awarding of Inducement Grant to New Chief Medical OfficerCarlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 07, 2023 8:45am
PALI .... P.O just announced
Always remember....all these Shitco's want to raise money.....it's the name of the game.....bury all the unsuspecting with worthless paper. Welcome to all the new Bagholders
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Sep 07, 2023 8:41am
RE:RE:PALI...Trading down 26 cents in the Pre-market open..duh ; )
Good ol MAW.V ....... 300,000,000 shares outstanding......fill yer boots Is this the way you promote by spamming everyones elses boards???? Good f'king luck
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 07, 2023 8:30am
New Press Release - Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Carlsbad, CA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 07, 2023 8:22am
PALI...Trading down 26 cents in the Pre-market open..duh ; )
Last at $1.18 on 775,000 shs traded this a.m. Close Prices Last 3 Months Price/volumes not adjusted for restructures Date Ex Sym Open
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 06, 2023 1:26pm
PALI .....125 million shares have traded and
your only up ~ $0.76 cents Please tell me another story
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 06, 2023 12:19pm
PALI....here it is again after the pump to $2
$1.43 pivot....gonna get smashed wait for it
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 06, 2023 10:01am
PALI....at support at $1.43...better rally up again....
if it doesn't ..... $1.16 is next....then the gap down
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Sep 06, 2023 9:19am
PALI.....Welcome to all the new Bagholders....ahem....
I mean "Chasers" this a.m.....your all about toget laid out with high priced worthless paper All on this news..... Palisade Bio Transforms GI-Focused Pipeline Through
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 06, 2023 8:45am
New Press Release - Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024 –Inflammatory bowel disease (IBD) represents a multi-billion dollar market opportunity with current therapies achieving a...
read article.
Prev
1
2
3
4
5
6
7
8
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden